Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.
INTRODUCTION: Despite the well-documented benefits of prophylaxis, treatment burden is still a barrier to adherence in patients with haemophilia. An extended half-life fusion protein linking recombinant FIX (rFIX) with human albumin (rIX-FP) has been developed for the treatment of patients with haemophilia B and is indicated for dosing up to every 14 days. This analysis evaluated real-world outcomes in patients switching to rIX-FP from the previous FIX product in Italy, Belgium and the UK. METHODS: Anonymised chart data were collected from the pre-existing medical records of patients with haem... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2020 |
Verlag/Hrsg.: |
Health Communications Inc.
|
Schlagwörter: | Albutrepenonacog alfa / Belgium / Factor IX / Haemophilia B / Italy / Medical records / Recombinant fusion proteins / United Kingdom |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26588181 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2078.1/236407 |